| Drug Name |
Crisaborole |
| Drug ID |
BADD_D02450 |
| Description |
Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.
This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and older. It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a good safety profile. Its structure contains a boron atom, which facilitates skin penetration and binding to the bimetal center of the phosphodiesterase 4 enzyme. It is currently under development as topical treatment of psoriasis. |
| Indications and Usage |
Intended for the topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older. |
| Marketing Status |
approved; investigational |
| ATC Code |
D11AH06 |
| DrugBank ID |
DB05219
|
| KEGG ID |
D10873
|
| MeSH ID |
C543085
|
| PubChem ID |
44591583
|
| TTD Drug ID |
D08NWF
|
| NDC Product Code |
0009-0211; 11722-066; 57572-0715; 60715-3211; 69037-0041; 51686-0005; 57572-0714; 17337-0546; 46438-0656; 58175-0622; 69575-4035; 69766-043; 55724-211 |
| UNII |
Q2R47HGR7P
|
| Synonyms |
crisaborole | Eucrisa | AN2728 | AN-2728 | 5-(4-cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole |
